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ABSTRACT
Introduction Systemic sclerosis (SSc; scleroderma) is 
a rare, chronic, autoimmune disease with a high level of 
burden, a significant impact on the ability to carry out daily 
activities, and a considerable negative impact on health- 
related quality of life. Non- pharmacological interventions 
could be provided to potentially improve mental and 
physical health outcomes. However, the effectiveness of 
non- pharmacological interventions on health and well- 
being among individuals with SSc has not been well 
established. The proposed living systematic review aims 
to identify and evaluate randomised controlled trial (RCT) 
evidence on the effectiveness of non- pharmacological and 
non- surgical interventions on mental and physical health 
outcomes and on the delivery of such services in SSc.
Methods and analysis Eligible studies will be RCTs 
that examine non- pharmacological and non- surgical 
interventions aimed at improving health outcomes among 
individuals with SSc or the delivery of services intended 
to improve healthcare or support of people with SSc (eg, 
support groups). All RCTs included in a previous systematic 
review that sought studies published between 1990 and 
March 2014 will be evaluated for inclusion. Additional 
trials will be sought from January 2014 onwards using 
a similar, augmented search strategy developed by a 
health sciences librarian. We will search the MEDLINE, 
Embase, CINAHL, PsycINFO, Cochrane Library and Web 
of Science databases and will not restrict by language. 
Two independent reviewers will determine the eligibility of 
identified RCTs and will extract data using a prespecified 
standardised form in DistillerSR. Meta- analyses will 
be considered if ≥2 eligible RCTs report similar non- 
pharmacological interventions and comparable health 
outcomes. We will conduct a qualitative synthesis for 
interventions that cannot be synthesised via meta- 
analysis.
Ethics and dissemination We will post initial and 
ongoing results via a website, publish results periodically 
via peer- reviewed journal publication, and present results 
at patient- oriented events.
PROSPERO registration number CRD42020219914.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a 
rare, chronic, autoimmune disease character-
ised by vasculopathy and excessive collagen 
production.1 Onset typically occurs at around 
50 years, and approximately 80% of people 
with SSc are women.1 2 SSc can affect multiple 
Strengths and limitations of this study
 ► Our living systematic review will be conducted us-
ing rigorous methods that comply with recommen-
dations in the Cochrane Handbook for Systematic 
Reviews of Interventions and Cochrane guidance 
for living systematic reviews, will include a risk 
of bias assessment, and will be conducted with 
peer- reviewed searches developed by a research 
librarian.
 ► Our systematic review will only include randomised 
controlled trial (RCT) evidence in order to avoid 
sources of bias more common in non- randomised 
trials, particularly pre–post comparisons.
 ► Our systematic review team includes experts in a 
wide variety of disciplines and areas of knowledge 
relevant to non- pharmacological care and treat-
ment in systemic sclerosis (SSc), as well as two 
patient collaborators with experience participating 
in research and providing first- hand insight into the 
needs of people with SSc.
 ► We will conduct a living systematic review; re-
sults will be continually updated as new evidence 
is published and will be distributed across well- 
established dissemination networks.
 ► Our search will seek eligible trials published from 
2014 onwards to supplement RCTs identified by a 
previous systematic review, meaning it is possible, 
although unlikely, that studies published prior to 
2014 may have been missed and will not be picked 
up by our searches.
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organ systems, including the skin, lungs, gastrointes-
tinal tract and heart. Common manifestations include 
Raynaud’s phenomenon, skin thickening, dyspnoea and 
cough, gastro- oesophageal reflux and other gastroin-
testinal symptoms.1 2 Disease presentation is extremely 
heterogeneous, and the course of the disease is highly 
unpredictable.1 2 People with SSc commonly experience 
hand function and mobility limitations, pain, fatigue, 
sleep problems, pruritus, depression and body image 
distress from disfigurement (eg, skin tightening, pigment 
changes, hand contractures, telangiectasias).3–9 These 
symptoms often have a considerable negative impact on 
health- related quality of life.5 10 11 There is currently no 
cure for SSc. Non- pharmacological interventions (eg, 
psychological, educational and rehabilitation interven-
tions) could potentially be used to improve quality of 
life.12
The effects of non- pharmacological and non- surgical 
interventions on health and well- being among individuals 
with SSc has not been well established. A previous system-
atic review13 of the effectiveness of non- pharmacological 
interventions in SSc identified 23 eligible studies 
published between 1990 and March 2014, of which 9 
were randomised controlled trials (RCTs). Included 
RCTs evaluated a multifaceted oral health intervention, 
multidisciplinary team care, and a variety of rehabilita-
tion strategies. They all included small numbers of partic-
ipants (range 25–53 total participants; median 35), and 
risk of bias was high in most trials.
Two more recent systematic reviews have evaluated 
exercise therapies14 and dietary interventions.15 A 2019 
review14 included nine studies on the safety and effec-
tiveness of exercise therapies published between 1990 
and 2019, of which four were RCTs. The four RCTs eval-
uated hand exercises, orofacial exercises and muscle 
strengthening exercises. The small numbers of partic-
ipants included in trials (range 4–48 total participants) 
and generally high risk of bias across trials, however, 
made it difficult to draw conclusions. A 2019 review15 of 
dietary interventions for gastrointestinal symptoms in 
SSc included three studies, published between 2011 and 
2017, but none were RCTs.
Since 2015, several larger, more robust RCTs on 
non- pharmacological interventions in SSc have been 
published, and others are in progress. Published 
RCTs include an evaluation of a personalised physical 
therapy programme (N=220),16 an internet- based self- 
management programme (N=247),17 a home- based 
exercise programme (N=44)18 and a comparison of 
two educational interventions in the rehabilitation of 
microstomia (N=63),19 for example. RCTs in progress 
with results expected in the next year include a web- based 
hand rehabilitation programme (N=466),20 a support- 
group leader educational programme (N targeted=180),21 
and a COVID-19 related mental health intervention (N 
targeted=162).22
The proposed living systematic review aims to iden-
tify and evaluate RCT evidence on the effectiveness of 
non- pharmacological and non- surgical interventions on 
health outcomes, including quality of life outcomes, and 
on the delivery of services in SSc. This will be accomplished 
via an initial systematic review followed by updates as new 
evidence is identified. The review will facilitate decisions 
on non- pharmacological healthcare options for people 
with SSc and will identify gaps in knowledge, which will 
facilitate planning of future research.
METHODS AND ANALYSIS
The living systematic review was registered in the PROS-
PERO prospective register of systematic reviews, and any 
future changes to the study protocol will be registered 
as amendments. The protocol was developed based on 
methodological guidance from the Cochrane Handbook 
for Systematic Reviews of Interventions and Cochrane 
guidance for living systematic reviews.23 24 The present 
protocol is reported according to Preferred Reporting 
Items for Systematic Review and Meta- Analysis Proto-
cols.25 The systematic review will be reported in accor-
dance with the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses statement.26 Initial searches 
were conducted on 30 November 2020, following regis-
tration and initial submission of this protocol for peer 
review. There is no planned end date.
Study eligibility
Eligible studies must be RCTs that examine non- 
pharmacological and non- surgical interventions aimed 
at improving health outcomes among individuals with 
SSc or the delivery of services intended to improve 
healthcare or support of people with SSc (eg, support 
groups). Non- randomised trials will be excluded, because 
of important limitations on the ability to draw conclu-
sions about intervention effectiveness, particularly when 
done without a control group. This is because many 
patients seek psychological, educational or rehabilita-
tion services when they are experiencing high levels of 
symptoms, and, on average, symptoms subside to some 
degree over the course of a trial, regardless of whether 
treatment is provided. For instance, in placebo groups in 
antidepressant trials and in usual care groups in depres-
sion psychotherapy trials, approximately 40% of patients 
with major depression remit.27 Since the course of SSc is 
highly unpredictable, and since symptom severity fluctu-
ates substantially, tests of interventions that use non- RCT 
designs, including pre–post designs, would be difficult 
to interpret and could generate potentially misleading 
results. RCTs address this problem by randomly allocating 
participants to trial arms.
Eligible trials must be conducted with participants with 
SSc, verified by clinical diagnosis or based on participant 
self- report. If an RCT includes some participants with 
SSc, but other participants who do not have SSc, it will 
be included only if results for those with SSc are reported 
separately or if at least 80% of participants have SSc. 
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Studies that report results from <10 participants per trial 
arm will be excluded.
Eligible interventions include, but are not limited to, 
physical or occupational therapy, rehabilitation, exer-
cise, psychological, self- management, educational, diet or 
nutrition, nursing, podiatry, and oral or dental hygiene 
interventions. All pharmacological interventions, or 
interventions with a drug component, will be excluded. 
Interventions will be classified as having a drug compo-
nent if any form of the active intervention ingredient was 
listed by the US Food and Drug Administration (FDA) 
in the Drugs@FDA database at the time of review. If not 
listed, investigators will consult other relevant sources to 
determine drug status. Use of probiotics will be included 
as a dietary or nutrition intervention if delivered as a 
food product similar to products that could be obtained 
outside of a medical intervention (eg, yoghurt). They will 
be excluded if they are products registered as a drug or 
delivered in pill format. Biologicals will be excluded, even 
if autologous (eg, skin grafting, stem cells), regardless of 
regulation status. Eligible intervention comparators will 
include: (1) any inactive control condition (eg, no treat-
ment, waitlist control, usual care) or (2) another eligible 
intervention designed to improve health outcomes in SSc 
or to improve delivery of services. At least one measured 
outcome must pertain to physical or psychological health 
or to aspects of delivery of health or support services (eg, 
e- health, support groups).
Search strategy
We will include all eligible RCTs from a previous system-
atic review,13 which searched for trials published between 
1990 and March 2014. Additional trials will be sought 
using a similar, augmented, search strategy from January 
2014 to the present, developed and performed by a health 
sciences librarian and peer- reviewed28 (see online supple-
mental file 1). Articles for review will be identified from 
the MEDLINE, Embase, CINAHL, PsycINFO, Cochrane 
Library and Web of Science databases. Searches will 
not be restricted by language or publication status. The 
previous review13 did not include trials on interventions to 
improve the delivery of health services or support services 
to individuals with SSc; however, since health services 
interventions have changed considerably in recent years, 
we will only consider delivery of services trials that have 
been published from January 2014 onwards.
In addition to database searches, we will manually 
review references from other relevant reviews, search clin-
ical trial registries and query authors of included RCTs 
about unpublished trials. After the initial search, auto-
mated searches will be set for monthly updates to facili-
tate continual review and update.
Selection of eligible studies
The results of the initial search and subsequent searches 
will be into the systematic review software DistillerSR 
(Evidence Partners, Ottawa, Canada) where duplicate 
references will be identified and removed. A two- stage 
process will be used to determine the eligibility of each 
publication, using a predefined inclusion and exclusion 
coding manual (see online supplemental file 2). Two inde-
pendent investigators will review the titles and abstracts 
of the articles identified through the search strategy in 
random order. If either of the two reviewers deems an 
article to be potentially eligible for inclusion, a full- text 
review of the article will be completed independently by 
two reviewers. Any disagreements that may arise at the 
full- text level will be resolved by consensus, with a third 
reviewer consulted as necessary.
Data extraction
For each included RCT, one investigator will extract data 
using a prespecified standardised form in DistillerSR. 
A second reviewer will validate the extracted data using 
the DistillerSR Quality Control function. Reviewers will 
extract (1) publication characteristics (eg, first author 
last name, publication year, journal, funding source, 
author conflicts of interest); (2) population character-
istics and demographics (eg, country, study eligibility 
criteria, recruitment method, number of participants, 
age, sex, type of SSc, disease duration, symptom thresh-
olds); (3) intervention components (eg, descriptions of 
the intervention and comparator, number of participants 
randomised to intervention and control groups, number 
of participants analysed in both groups, intervention 
length, intervention setting (where delivered), number 
of sessions, length of sessions, qualifications of interven-
tion providers, tailoring, modifications and fidelity adher-
ence, as described by the Template for Intervention and 
Description and Replication Checklist)29 and (4) health 
or service provision outcomes. See online supplemental 
file 3 for variables to be extracted. Disagreements will be 
resolved by consensus, with a third investigator consulted 
as necessary.
Two reviewers will independently assess included 
studies for risk of bias using the revised cochrane risk of 
bias tool for randomised trials.30 The tool includes five 
domains through which bias could be introduced; they 
are assessed and scored according to whether study char-
acteristics reflect low, high or some concerns regarding 
risk of bias. Domains include (1) risk of bias due to the 
randomisation process; (2) deviations from the intended 
intervention; (3) missing outcome data; (4) outcome 
measurement and (5) selection of the reported result. 
Disagreements will be resolved by consensus, and a third 
investigator will be consulted as necessary.
Data analysis
Meta- analyses will be considered if ≥2 eligible RCTs 
report similar non- pharmacological interventions and 
comparable health outcomes and if the trials are of suffi-
ciently high general quality to draw conclusions, based 
on judgements about risk of bias, sample size and risk 
of publication bias. RCTs that are not meta- analysed 
will be described qualitatively. When studies are synthe-
sised meta- analytically, data will be pooled using the 
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DerSimonian Laird random effects model.31 For dichot-
omous outcomes, we will report relative risks between 
groups with 95% CIs. For continuous outcomes, Hedges’ 
g will be used to calculate standardised mean differences 
for continuous outcomes.32 We will prioritise postinter-
vention comparisons adjusted for baseline values, then 
unadjusted comparisons, followed by comparisons of 
change scores. If multiple measures are used to assess 
the same outcome in a study, effect sizes from all rele-
vant measures will be synthesised within the study before 
being entered into the meta- analysis. If we are not able to 
use a study’s data in a meta- analysis because, for instance, 
only p values are reported, we will begin by querying the 
authors for the relevant results. If the full results are not 
able to be obtained, we will present what was provided in 
publications in tables. The I2 statistic will be used to assess 
the heterogeneity of included trials.33 Publication bias 
will be examined using funnel plots if there are at least 10 
studies included for a given intervention.
Patient and public involvement
The research team includes people with SSc who are 
actively involved as members of the Scleroderma Patient- 
centered Intervention Network Patient (SPIN) Advisory 
Board. They have provided input on the protocol and 
study design and will be involved in review, interpretation 
and dissemination of results.
ETHICS AND DISSEMINATION
Ethics approval was not required for this systematic review 
because we will be including only published aggregate 
data.
To disseminate results, we will post initial and ongoing 
results via a website (https://www. spinsclero. com/ en/ 
projects/ non- pharm- interventions) and publish results 
periodically via peer- reviewed journal publications. 
Updated results will be updated to the website as soon as 
new trials are identified. We will submit updated results 
from journal publication when the author team identifies 
that there are substantive changes in the evidence base. 
We will further disseminate results to the international 
scleroderma patient community through the SPIN social 
media accounts and by distribution of announcements to 
SPIN’s patient organisation partners. Systematic review 
team members present regularly at national and inter-
national scleroderma patient congresses, and we plan to 
disseminate results at those congresses.
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Supplementary File 1. Search strategies  
Ovid MEDLINE(R) ALL  
 
1  exp Nutrition Therapy/ 
2  exp Diet/ 
3  diet therapy.fs. 
4  exp Dietary Supplements/ 
5  (nutrition or diet or dietary or nutritional or probiotic*).tw,kf. 
6  1 or 2 or 3 or 4 or 5 
7  (physical therap* or physiotherap* or physio therap*).ti,ab,kf. 
8  Physical Therapists/ or Physical Therapy Modalities/ 
9  Physical Therapy Specialty/ 
10  occupational therap*.ti,ab,kf. 
11  exp Physical Therapy Modalities/ 
12  Occupational Therapy/ 
13  exp balneology/ or Massage/ or Hyperthermia, Induced/ or baths/ or vocational 
rehabilitation/ or recreation therapy/ or splints/ or orthotic devices/ or energy metabolism/ 
or podiatry/ or cryotherapy/ 
14  (hydrotherapy or balneology or balneotherapy or massage* or skin mobilization or 
thermotherapy or induced hyperthermia or paraffin wax or wax bath* or recreation 
therapy or splint* or orthotic* or joint protection or activity pacing or energy 
conservation or podiatr* or foot care or cryotherap*).tw,kf. 
15  7 or 8 or 9 or 10 or 11 or 12 or 13 or 14  
16  exp Adaptation, Psychological/  
17  exp Psychotherapy/  
18  exp Counseling/  
19  "Self-Help Groups"/  
20  "Social Support"/  
21  Patient Education as Topic/ or "Early intervention (education)"/  
22  ((non-surgical or psychological or behavio*r or behavio*ral or cognitive or psychosocial 
or psycho-social or psychoeducation*) adj3 (intervention* or treatment* or therap* or 
program* or modification)).tw,kf.  
23  (Coping adj (skill* or behavio?r*)).tw,kf.  
24  Mindfulness.tw,kf. or mindfulness/  
25  Patient education.tw,kf.  
26  (group therapy or support group* or self help group*).tw,kf.  
27  ((peer or psychosocial or social or patient) adj support).tw,kf.  
28  (Psychotherapy or psychotherapies or CBT).tw,kf. 
29  counsel*ing.tw,kf.  
30  self-management.tw,kf.  
31  psychoeducation.tw,kf.  
32  exp health education/ or self care/ or self management/ or Self-Help Devices/  
33  (assistive technolog* or assistive device* or education* or health literacy or health 
information or self care or Self-Help Device*).tw,kf.  
34  or/16-33  
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35  telemedicine/ or telerehabilitation/ or remote consultation/ or cell phone/ or text 
messaging/  
36  ((mobile adj1 (health or rehabilitation)) or tele health or telehealth or telemedicine or e-
health or ehealth or m-health or mhealth or mobile based or (virtual adj1 (medicine or 
rehabilitation)) or ((remote or distance) adj1 (medicine or rehabilitation or consultation)) 
or videoconferenc* or video conferenc* or tele conferenc* or teleconferenc* or tele 
education or tele-education or telementoring or tele-mentoring or tele-care or telecare or 
live video*).tw,kf.  
37  (cell phone* or text messag*).tw,kf.  
38  35 or 36 or 37  
39  Dental Health Services/ or Oral Health/ or Oral Hygiene/ or dental care/ or dental care for 
chronically ill/ or dental care for disabled/  
40  ((Oral or dental or periodontal or Gingival) adj2 (rehabilitation or health or pathology or 
hygiene or care or therap* or treatment* or activit* or exercise* or disease*)).tw,kf.  
41  39 or 40  
42  exp Exercise/ or exp Exercise Therapy/ or physical endurance/ or sports/ or motor 
activity/ or physical fitness/  
43  (exercis* or stretching or resistance training or strength training or running or jogging or 
swimming or walking or physical endurance or sports or sport or physical activity or 
treadmill* or bicycling or cycling or physical conditioning or muscle strength*).tw,kf.  
44  42 or 43  
45  ((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) adj (treatment or intervention or therap* or 
management)).tw,kf.  
46  *Rehabilitation/ or rehabilitation.fs. or rehabilitation.tw,kf. 
47  45 or 46  
48  Acupuncture Therapy/ or Cupping Therapy/ or Dry Needling/ or Bioresonance Therapy/ 
or Homeopathy/ or Medicine, Traditional/ or exp Mind-Body Therapies/ or exp 
Musculoskeletal Manipulations/ or Naturopathy/ or Prolotherapy/ or Reflexotherapy/ or 
exp Sensory Art Therapies/ or Spiritual Therapies/ or exp phototherapy/ or laser therapy/  
49  (Acupuncture or Cupping or Dry Needling or Bioresonance or Homeopath* or 
Traditional medicine or Mind-Body Therap* or Aromatherap* or Biofeedback or 
Breathing or Hypnosis or Imagery or Laughter Therap* or Meditation or Mental Healing 
or Psychodrama or Psychophysiology or Relaxation Therap* or Tai Ji or Tai chi or 
Therapeutic Touch* or Yoga or Musculoskeletal Manipulation* or applied Kinesiology 
or Chiropractic or Osteopathic or Soft Tissue therap* or Naturopath* or Prolotherap* or 
Reflexotherap* or Sensory Art Therap* or Acoustic Stimulation or Art Therap* or Color 
Therap* or Dance Therap* or Music Therap* or Play Therap* or Spiritual Therap* or 
Relaxation Technique* or reflexolog* or phototherap* or light therap* or laser*).tw,kf.  
50  ((Alternative or Complementary) adj2 (medicine or therap* or treatment*)).tw,kf.  61064 
51  48 or 49  
52  6 or 15 or 34 or 38 or 41 or 44 or 47 or 51  
53  exp Scleroderma, Systemic/ or (scleroderma* or systemic sclerosis or CREST 
syndrome*).ti,ab,kf.  
54  52 and 53  
55  randomized controlled trial.pt.  
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56  controlled clinical trial.pt.  
57  randomi?ed.ab.  
58  placebo.ab.  
59  drug therapy.fs.  
60  randomly.ab.  
61  trial.ab.  
62  groups.ab.  
63  or/55-62  
64  exp animals/ not humans.sh. 
65  63 not 64  




1 exp *diet therapy/ 
2 exp *diet/ 
3 *dietary supplement/ 
4 (nutrition or diet or dietary or nutritional or probiotic*).tw,kw. 
5 1 or 2 or 3 or 4 
6 exp *physiotherapy/ 
7 *physiotherapist/ 
8 *occupational therapy/ 
9 occupational therap*.tw,kw. 
10 (physical therap* or physiotherap* or physio therap*).tw,kw. 
11 exp *balneotherapy/ 
12 exp *massage/ 
13 exp *bath/ 
14 *vocational rehabilitation/ 
15 *recreational therapy/ 
16 exp *splint/ 
17 exp *orthosis/ 
18 *energy conservation/ 
19 *podiatry/ 
20 *cryotherapy/ 
21 exp *thermotherapy/ 
22 *induced hypothermia/ 
23 *foot care/ 
24 or/6-23 
25 *coping behavior/ or *meaning-making/ or *stress management/ 
26 exp *psychotherapy/ 
27 exp *counseling/ 
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28 exp *self help/ 
29 *social support/ 
30 *patient education/ 
31 
((non-surgical or psychological or behavio*r or behavio*ral or cognitive or psychosocial or 
psycho-social or psychoeducation*) adj3 (intervention* or treatment* or therap* or 
program* or modification)).tw,kw. 
32 (Coping adj (skill* or behavio?r*)).tw,kw. 
33 exp *mindfulness/ 
34 (Patient education or mindfulness).tw,kw. 
35 (group therapy or support group* or self help group*).tw,kw. 
36 ((peer or psychosocial or social or patient) adj support).tw,kw. 




41 exp *health education/ 
42 *self care/ 
43 *self help device/ 
44 
(assistive technolog* or assistive device* or education* or health literacy or health 
information or self care or Self-Help Device*).tw,kw. 
45 or/25-44 
46 exp *telemedicine/ 
47 exp *mobile phone/ 
48 *text messaging/ 
49 
((mobile adj1 (health or rehabilitation)) or tele health or telehealth or telemedicine or e-
health or ehealth or m-health or mhealth or mobile based or (virtual adj1 (medicine or 
rehabilitation)) or ((remote or distance) adj1 (medicine or rehabilitation or consultation)) or 
videoconferenc* or video conferenc* or tele conferenc* or teleconferenc* or tele education 
or tele-education or telementoring or tele-mentoring or tele-care or telecare or live 
video*).tw,kw. 
50 (cell phone* or text messag*).tw,kw. 
51 or/46-50 
52 *dental procedure/ 
53 *mouth hygiene/ 
54 
((Oral or dental or periodontal or Gingival) adj2 (rehabilitation or health or pathology or 
hygiene or care or therap* or treatment* or activit* or exercise* or disease*)).tw,kw. 
55 or/52-54 
56 exp *exercise/ 
57 exp *kinesiotherapy/ 
58 exp *sport/ 
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59 exp *motor activity/ 
60 *fitness/ 
61 
(exercis* or stretching or resistance training or strength training or running or jogging or 
swimming or walking or physical endurance or sports or sport or physical activity or 
treadmill* or bicycling or cycling or physical conditioning or muscle strength*).tw,kw. 
62 or/56-61 
63 
((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 






((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) adj (treatment or intervention or therap* or 
management)).tw,kw. 
68 or/63-67 
69 exp *acupuncture/ 
70 
*alternative medicine/ or *bioresonance therapy/ or *cupping therapy/ or dry needling/ or 
*homeopathy/ or *naturopathy/ or *prolotherapy/ 
71 exp *musculoskeletal manipulation/ 
72 *art therapy/ 
73 *spiritual healing/ 
74 exp *phototherapy/ 
75 
(Acupuncture or Cupping or Dry Needling or Bioresonance or Homeopath* or Traditional 
medicine or Mind-Body Therap* or Aromatherap* or Biofeedback or Breathing or 
Hypnosis or Imagery or Laughter Therap* or Meditation or Mental Healing or 
Psychodrama or Psychophysiology or Relaxation Therap* or Tai Ji or Tai chi or 
Therapeutic Touch* or Yoga or Musculoskeletal Manipulation* or applied Kinesiology or 
Chiropractic or Osteopathic or Soft Tissue therap* or Naturopath* or Prolotherap* or 
Reflexotherap* or Sensory Art Therap* or Acoustic Stimulation or Art Therap* or Color 
Therap* or Dance Therap* or Music Therap* or Play Therap* or Spiritual Therap* or 
Relaxation Technique* or reflexolog* or phototherap* or light therap* or laser*).tw,kw. 
76 ((Alternative or Complementary) adj2 (medicine or therap* or treatment*)).tw,kw. 
77 or/69-76 
78 5 or 24 or 45 or 51 or 62 or 68 or 77 
79 exp *scleroderma/ 
80 (scleroderma* or systemic sclerosis or CREST syndrome*).tw,kw. 
81 79 or 80 
82 78 and 81 
83 "randomized controlled trial (topic)"/ 
84 Randomized Controlled Trial/ 
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85 Randomization/ 
86 Double Blind Procedure/ 
87 single blind procedure/ 
88 placebo/ 
89 (random* or sham or placebo*).ti,ab,hw. 
90 ((singl* or doubl*) adj (blind* or dumm* or mask*)).ti,ab,hw. 
91 ((tripl* or trebl*) adj (blind* or dumm* or mask*)).ti,ab,hw. 
92 or/83-91 
93 82 and 92 
94 
(201403* or 201404* or 201405* or 201406* or 201407* or 201408* or 201409* or 
201410* or 201411* or 201412* or 2015* or 2016* or 2017* or 2018* or 2019* or 
2020*).dc. 





2 exp dietary supplements/ 
3 Diets/ 
4 (nutrition or diet or dietary or nutritional or probiotic*).tw,id. 
5 1 or 2 or 3 or 4 
6 physical therapy/ 
7 (physical therap* or physiotherap* or physio therap*).tw,id. 
8 occupational therapy/ 
9 occupational therap*.tw,id. 
10 Massage/ 
11 vocational rehabilitation/ or disability management/ or rehabilitation counseling/ 
12 
recreation therapy/ or creative arts therapy/ or exp adventure therapy/ or art therapy/ or 
dance therapy/ or horticulture therapy/ or movement therapy/ or music therapy/ 
13 
(hydrotherapy or balneology or balneotherapy or massage* or skin mobilization or 
thermotherapy or induced hyperthermia or paraffin wax or wax bath* or recreation therapy 
or splint* or orthotic* or joint protection or activity pacing or energy conservation or 
podiatr* or foot care or cryotherap*).tw,id. 
14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15 coping behavior/ or emotional adjustment/ 
16 exp psychotherapy/ 
17 exp counseling/ 
18 exp Support Groups/ or exp Self-Help Techniques/ 
19 exp Social Support/ 
20 client education/ 
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21 mindfulness/ or mindfulness-based interventions/ 
22 
((non-surgical or psychological or behavio*r or behavio*ral or cognitive or psychosocial or 
psycho-social or psychoeducation*) adj3 (intervention* or treatment* or therap* or 
program* or modification)).tw,id. 
23 (Coping adj (skill* or behavio?r*)).tw,id. 
24 Mindfulness.tw,id. 
25 Patient education.tw,id. 
26 (group therapy or support group* or self help group*).tw,id. 
27 ((peer or psychosocial or social or patient) adj support).tw,id. 




32 health education/ 
33 
(assistive technolog* or assistive device* or education* or health literacy or health 
information or self care or Self-Help Device*).tw,id. 
34 assistive technology/ or medical therapeutic devices/ 
35 or/15-34 
36 exp telemedicine/ 
37 exp mobile phones/ or text messaging/ 
38 
((mobile adj1 (health or rehabilitation)) or tele health or telehealth or telemedicine or e-
health or ehealth or m-health or mhealth or mobile based or (virtual adj1 (medicine or 
rehabilitation)) or ((remote or distance) adj1 (medicine or rehabilitation or consultation)) or 
videoconferenc* or video conferenc* or tele conferenc* or teleconferenc* or tele education 
or tele-education or telementoring or tele-mentoring or tele-care or telecare or live 
video*).tw,id. 
39 (cell phone* or text messag*).tw,id. 
40 36 or 37 or 38 or 39 
41 exp Oral Health/ 
42 exp Dental Treatment/ 
43 exp Dental Health/ 
44 
((Oral or dental or periodontal or Gingival) adj2 (rehabilitation or health or pathology or 
hygiene or care or therap* or treatment* or activit* or exercise* or disease*)).tw,id. 
45 41 or 42 or 43 or 44 
46 exp exercise/ 
47 exp Physical Endurance/ 
48 exp Sports/ 
49 exp Physical Fitness/ 
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50 
(exercis* or stretching or resistance training or strength training or running or jogging or 
swimming or walking or physical endurance or sports or sport or physical activity or 
treadmill* or bicycling or cycling or physical conditioning or muscle strength*).tw,id. 
51 46 or 47 or 48 or 49 or 50 
52 rehabilitation/ or cognitive rehabilitation/ or psychosocial rehabilitation/ 
53 
(((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) adj (treatment or intervention or therap* or management)) 
or rehabilitation).tw,id. 
54 52 or 53 
55 alternative medicine/ or acupuncture/ or faith healing/ 
56 exp Phototherapy/ 
57 exp Laser Irradiation/ 
58 mind body therapy/ 
59 exp Yoga/ 
60 
(Acupuncture or Cupping or Dry Needling or Bioresonance or Homeopath* or Traditional 
medicine or Mind-Body Therap* or Aromatherap* or Biofeedback or Breathing or 
Hypnosis or Imagery or Laughter Therap* or Meditation or Mental Healing or 
Psychodrama or Psychophysiology or Relaxation Therap* or Tai Ji or Tai chi or 
Therapeutic Touch* or Yoga or Musculoskeletal Manipulation* or applied Kinesiology or 
Chiropractic or Osteopathic or Soft Tissue therap* or Naturopath* or Prolotherap* or 
Reflexotherap* or Sensory Art Therap* or Acoustic Stimulation or Art Therap* or Color 
Therap* or Dance Therap* or Music Therap* or Play Therap* or Spiritual Therap* or 
Relaxation Technique* or reflexolog* or phototherap* or light therap* or laser*).tw,id. 
61 ((Alternative or Complementary) adj2 (medicine or therap* or treatment*)).tw,id. 
62 or/55-61 
63 (scleroderma* or systemic sclerosis or CREST syndrome*).tw,id. 
64 skin disorders/ 
65 "Sclerosis (Nervous System)"/ 
66 63 or 64 or 65 
67 14 or 35 or 40 or 45 or 51 or 54 or 62 
68 66 and 67 
69 
(201403* or 201404* or 201405* or 201406* or 201407* or 201408* or 201409* or 
201410* or 201411* or 201412* or 2015* or 2016* or 2017* or 2018* or 2019* or 
2020*).up. 






Search Terms  
S89  S87 AND S88  
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S88  EM 20140301-2020*  
S87  S74 AND S86  
S86  
S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81 OR S82 OR 
S83 OR S84 OR S85  
S85  TX allocat* random*  
S84  (MH "Quantitative Studies")  
S83  (MH "Placebos")  
S82  TX placebo*  
S81  TX random* allocat*  
S80  (MH "Random Assignment")  
S79  TX randomi* control* trial*  
S78  
S4 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 
blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 
mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )  
S77  TX clinic* n1 trial*  
S76  PT Clinical trial  
S75  (MH "Clinical Trials+")  
S74  S72 AND S73  
S73  S6 OR S18 OR S36 OR S42 OR S47 OR S54 OR S58 OR S69  
S72  S70 OR S71  
S71  
TI ( (scleroderma* or systemic sclerosis or CREST syndrome*) ) OR 
AB ( (scleroderma* or systemic sclerosis or CREST syndrome*) )  
S70  (MH "Scleroderma, Systemic+")  
S69  
S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR 
S67 OR S68  
S68  
TI ( ((Alternative or Complementary) N2 (medicine or therap* or 
treatment*)) ) OR AB ( ((Alternative or Complementary) N2 
(medicine or therap* or treatment*)) )  
S67  
TI ( (Acupuncture or Cupping or Dry Needling or Bioresonance or 
Homeopath* or Traditional medicine or Mind-Body Therap* or 
Aromatherap* or Biofeedback or Breathing or Hypnosis or Imagery 
or Laughter Therap* or Meditation or Mental Healing or 
Psychodrama or Psychophysiology or Relaxation Therap* or Tai Ji or 
Tai chi or Therapeutic Touch* or Yoga or Musculoskeletal 
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Manipulation* or applied Kinesiology or Chiropractic or Osteopathic 
or Soft Tissue therap* or Naturopath* or Prolotherap* or 
Reflexotherap* or Sensory Art Therap* or Acoustic Stimulation or 
Art Therap* or Color Therap* or Dance Therap* or Music Therap* or 
Play Therap* or Spiritual Therap* or Relaxation Technique* or 
reflexolog* or phototherap* or light therap* or laser*) ) OR AB ( 
(Acupuncture or Cupping or Dry Needling or Bioresonance or 
Homeopath* or Traditional medicine or Mind-Body Therap* or 
Aromatherap* or Biofeedback or Breathing or Hypnosis or Imagery 
or Laughter Therap* or Meditation or Mental Healing or 
Psychodrama or Psychophysiology or Relaxation Therap* or Tai Ji or 
Tai chi or Therapeutic Touch* or Yoga or Musculoskeletal 
Manipulation* or applied Kinesiology or Chiropractic or Osteopathic 
or Soft Tissue therap* or Naturopath* or Prolotherap* or 
Reflexotherap* or Sensory Art Therap* or Acoustic Stimulation or 
Art Therap* or Color Therap* or Dance Therap* or Music Therap* or 
Play Therap* or Spiritual Therap* or Relaxation Technique* or 
reflexolog* or phototherap* or light therap* or laser*) )  
S66  (MH "Laser Therapy+")  
S65  (MH "Phototherapy+")  
S64  (MH "Prolotherapy")  
S63  (MH "Manual Therapy")  
S62  (MH "Mind Body Techniques+")  
S61  (MH "Dry Needling")  
S60  (MH "Cupping Therapy")  
S59  
(MH "Acupuncture") OR (MH "Homeopathy") OR (MH "Medicine, 
Traditional") OR (MH "Naturopathy") OR (MH "Alternative 
Therapies")  
S58  S55 OR S56 OR S57  
S57  TI rehabilitation OR AB rehabilitation  
S56  MW "RH"  
S55  
TI ( ((non pharmacological or nonpharmacological or 
multidisciplinary or multicomponent or interdisciplinary or 
multimodal) N1 (treatment or intervention or therap* or 
management)) ) OR AB ( ((non pharmacological or 
nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) N1 (treatment or intervention or 
therap* or management)) )  
S54  S48 OR S49 OR S50 OR S51 OR S52 OR S53  
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S53  
TI ( (exercis* or stretching or resistance training or strength training 
or running or jogging or swimming or walking or physical endurance 
or sports or sport or physical activity or treadmill* or bicycling or 
cycling or physical conditioning or muscle strength*) ) OR AB ( 
(exercis* or stretching or resistance training or strength training or 
running or jogging or swimming or walking or physical endurance or 
sports or sport or physical activity or treadmill* or bicycling or 
cycling or physical conditioning or muscle strength*) )  
S52  (MH "Physical Fitness+")  
S51  (MH "Motor Activity+")  
S50  (MH "Sports+")  
S49  (MH "Physical Endurance+")  
S48  (MH "Exercise+") OR (MH "Therapeutic Exercise+")  
S47  S43 OR S44 OR S45 OR S46  
S46  
TI ( ((Oral or dental or periodontal or Gingival) N2 (rehabilitation or 
health or pathology or hygiene or care or therap* or treatment* or 
activit* or exercise* or disease*)) ) OR AB ( ((Oral or dental or 
periodontal or Gingival) N2 (rehabilitation or health or pathology or 
hygiene or care or therap* or treatment* or activit* or exercise* or 
disease*)) )  
S45  (MH "Oral Hygiene")  
S44  (MH "Oral Health")  
S43  (MH "Dental Health Services+")  
S42  S37 OR S38 OR S39 OR S40 OR S41  
S41  
TI ( (cell phone* or text messag*) ) OR AB ( (cell phone* or text 
messag*) )  
S40  
TI ( ((mobile N1 (health or rehabilitation)) or tele health or telehealth 
or telemedicine or e-health or ehealth or m-health or mhealth or 
mobile based or (virtual N1 (medicine or rehabilitation)) or ((remote 
or distance) N1 (medicine or rehabilitation or consultation)) or 
videoconferenc* or video conferenc* or tele conferenc* or 
teleconferenc* or tele education or tele-education or telementoring or 
tele-mentoring or tele-care or telecare or live video*) ) OR AB ( 
((mobile N1 (health or rehabilitation)) or tele health or telehealth or 
telemedicine or e-health or ehealth or m-health or mhealth or mobile 
based or (virtual N1 (medicine or rehabilitation)) or ((remote or 
distance) N1 (medicine or rehabilitation or consultation)) or 
videoconferenc* or video conferenc* or tele conferenc* or 
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teleconferenc* or tele education or tele-education or telementoring or 
tele-mentoring or tele-care or telecare or live video*) )  
S39  (MH "Cellular Phone+")  
S38  (MH "Remote Consultation")  
S37  (MH "Telehealth+")  
S36  
S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR 
S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR 
S35  
S35  (MH "Assistive Technology Devices+")  
S34  (MH "Self Care") OR (MH "Self-Management")  
S33  (MH "Health Education")  
S32  
TI ( (assistive technolog* or assistive device* or education* or health 
literacy or health information or self care or Self-Help Device*) ) OR 
AB ( (assistive technolog* or assistive device* or education* or 
health literacy or health information or self care or Self-Help 
Device*) )  
S31  
TI ( (Psychotherapy or psychotherapies or CBT or counsel*ing or 
self-management or psychoeducation) ) OR AB ( (Psychotherapy or 
psychotherapies or CBT or counsel*ing or self-management or 
psychoeducation) )  
S30  
TI ( ((peer or psychosocial or social or patient) N1 support) ) OR AB 
( ((peer or psychosocial or social or patient) N1 support) )  
S29  
TI ( (group therapy or support group* or self help group*) ) OR AB ( 
(group therapy or support group* or self help group*) )  
S28  
TI ( Patient education or mindfulness ) OR AB ( Patient education or 
Mindfulness )  
S27  (MH "Mindfulness")  
S26  
TI ( (Coping N1 (skill* or behavio?r*)) ) OR AB ( (Coping N1 (skill* 
or behavio?r*)) )  
S25  
TI ( (Coping N (skill* or behavio?r*)) ) OR AB ( (Coping N (skill* or 
behavio?r*)) )  
S24  
TI ( ((non-surgical or psychological or behavio*r or behavio*ral or 
cognitive or psychosocial or psycho-social or psychoeducation*) N3 
(intervention* or treatment* or therap* or program* or modification)) 
) OR AB ( ((non-surgical or psychological or behavio*r or 
behavio*ral or cognitive or psychosocial or psycho-social or 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-047428:e047428. 11 2021;BMJ Open, et al. Discepola M-N
psychoeducation*) N3 (intervention* or treatment* or therap* or 
program* or modification)) )  
S23  (MH "Patient Education+")  
S22  (MH "Support Groups+")  
S21  (MH "Counseling+")  
S20  (MH "Psychotherapy+")  
S19  (MH "Adaptation, Psychological+")  
S18  
S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 
OR S16 OR S17  
S17  
TI ( (hydrotherapy or balneology or balneotherapy or massage* or 
skin mobilization or thermotherapy or induced hyperthermia or 
paraffin wax or wax bath* or recreation therapy or splint* or orthotic* 
or joint protection or activity pacing or energy conservation or 
podiatr* or foot care or cryotherap*) ) OR AB ( (hydrotherapy or 
balneology or balneotherapy or massage* or skin mobilization or 
thermotherapy or induced hyperthermia or paraffin wax or wax bath* 
or recreation therapy or splint* or orthotic* or joint protection or 
activity pacing or energy conservation or podiatr* or foot care or 
cryotherap*) )  
S16  (MH "Podiatry")  
S15  (MH "Energy Conservation, Metabolic")  
S14  (MH "Orthoses+")  
S13  (MH "Splints")  
S12  (MH "Recreational Therapy")  
S11  
(MH "Rehabilitation, Vocational") OR (MH "Dance Therapy") OR 
(MH "Home Rehabilitation") OR (MH "Music Therapy") OR (MH 
"Rehabilitation, Athletic") OR (MH "Rehabilitation, Cognitive") OR 
(MH "Rehabilitation, Psychosocial") OR (MM "Rehabilitation") OR 
(MH "Art Therapy") OR (MH "Manual Therapy+")  
S10  
TI ( (physical therap* or physiotherap* or physio therap* or 
occupational therap*) ) OR AB ( (physical therap* or physiotherap* 
or physio therap* or occupational therap*) )  
S9  (MH "Occupational Therapy+")  
S8  (MH "Physical Therapists")  
S7  (MH "Physical Therapy+")  
S6  S1 OR S2 OR S3 OR S4 OR S5  
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S5  
TI ( (nutrition or diet or dietary or nutritional or probiotic*) ) OR AB 
( (nutrition or diet or dietary or nutritional or probiotic*) )  
S4  (MW "DH")  
S3  (MH "Dietary Supplements+")  
S2  (MH "Diet+")  




#1 ((nutrition or diet or dietary or nutritional or probiotic* or (physical NEXT therap*) or 
physiotherap* or   (physio NEXT therap*) or hydrotherapy or balneology or balneotherapy 
or massage* or “skin mobilization” or thermotherapy or “induced hyperthermia” or 
“paraffin wax” or “wax bath*” or “recreation therapy” or splint* or orthotic* or “joint 
protection” or “activity pacing” or “energy conservation” or podiatr* or “foot care” or 
cryotherap* or Acupuncture or Cupping or “Dry Needling” or Bioresonance or 
Homeopath* or “Traditional medicine” or Aromatherap* or Biofeedback or Breathing or 
Hypnosis or Imagery or “Laughter Therap*” or Meditation or “Mental Healing” or 
Psychodrama or Psychophysiology or (Relaxation NEXT Therap*) or “Tai Ji” or “Tai chi” 
or (Therapeutic NEXT Touch*) or Yoga or (Musculoskeletal NEXT Manipulation*) or 
“applied Kinesiology” or Chiropractic or Osteopathic or (“Soft Tissue” NEXT therap*) or 
Naturopath* or Prolotherap* or Reflexotherap* or “Acoustic Stimulation” or (Art NEXT 
Therap*) or (Color NEXT Therap*) or (Dance NEXT Therap*) or (Music NEXT Therap*) 
or (Play NEXT Therap*) or (Spiritual NEXT Therap*) or (Relaxation NEXT Technique*) 
or reflexolog* or phototherap* or (light NEXT therap*) or laser* or Mindfulness or 
“Patient education” or “group therapy” or “support group*” or “self help”)):ti,ab,kw 
#2 ((non-surgical or psychological or behavior* or behaviour* or cognitive or psychosocial or 
psycho-social or psychoeducation*) NEXT/3 (intervention* or treatment* or therap* or 
program* or modification)):ti,ab,kw 
#3 (Coping NEXT/1 (skill* or behavior* or behaviour*)):ti,ab,kw 
#4 (peer or psychosocial or social or patient) NEXT/1 (support):ti,ab,kw 
#5 (Psychotherapy or psychotherapies or CBT or counseling or counselling or “self-
management” or psychoeducation or (assistive NEXT technolog*) or (assistive NEXT 
device*) or education* or “health literacy” or “health information” or “self care” or 
exercis* or stretching or “resistance training” or “strength training” or running or jogging 
or swimming or walking or “physical endurance” or sports or sport or “physical activity” 
or treadmill* or bicycling or cycling or “physical conditioning” or “muscle strength*” or 
rehabilitation):ti,ab,kw 
#6 ((mobile NEXT/1 (health or rehabilitation)) or tele health or telehealth or telemedicine or 
e-health or ehealth or m-health or mhealth or mobile based or (virtual NEXT/1 (medicine 
or rehabilitation)) or ((remote or distance) NEXT/1 (medicine or rehabilitation or 
consultation)) or videoconferenc* or video conferenc* or tele conferenc* or teleconferenc* 
or tele education or tele-education or telementoring or tele-mentoring or tele-care or 
telecare or live video* or cell phone* or text messag*):ti,ab,kw 
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#7 ((Oral or dental or periodontal or Gingival) NEXT/2 (rehabilitation or health or pathology 
or hygiene or care or therap* or treatment* or activit* or exercise* or disease*)):ti,ab,kw 
#8 ((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) NEXT/1 (treatment or intervention or therap* or 
management)):ti,ab,kw 
#9 ((Alternative or Complementary) NEXT/2 (medicine or therap* or treatment*)) 
#10 {OR #1-#9} 
#11 (scleroderma* or “systemic sclerosis” or CREST syndrome*) 
#12 #10 AND #11 
 
Web of Science 
 
((nutrition or diet or dietary or nutritional or probiotic* or (physical NEAR/1 therap*) or 
physiotherap* or   (physio NEAR/1 therap*) or hydrotherapy or balneology or balneotherapy or 
massage* or “skin mobilization” or thermotherapy or “induced hyperthermia” or “paraffin wax” 
or “wax bath*” or “recreation therapy” or splint* or orthotic* or “joint protection” or “activity 
pacing” or “energy conservation” or podiatr* or “foot care” or cryotherap* or Acupuncture or 
Cupping or “Dry Needling” or Bioresonance or Homeopath* or “Traditional medicine” or 
Aromatherap* or Biofeedback or Breathing or Hypnosis or Imagery or “Laughter Therap*” or 
Meditation or “Mental Healing” or Psychodrama or Psychophysiology or (Relaxation NEAR/1 
Therap*) or “Tai Ji” or “Tai chi” or (Therapeutic NEAR/1 Touch*) or Yoga or (Musculoskeletal 
NEAR/1 Manipulation*) or “applied Kinesiology” or Chiropractic or Osteopathic or (“Soft 
Tissue” NEAR/1 therap*) or Naturopath* or Prolotherap* or Reflexotherap* or “Acoustic 
Stimulation” or (Art NEAR/1 Therap*) or (Color NEAR/1 Therap*) or (Dance NEAR/1 
Therap*) or (Music NEAR/1 Therap*) or (Play NEAR/1 Therap*) or (Spiritual NEAR/1 
Therap*) or (Relaxation NEAR/1 Technique*) or reflexolog* or phototherap* or (light NEAR/1 
therap*) or laser* or Mindfulness or “Patient education” or “group therapy” or (support NEAR/1 
group*) or “self help”) 
 
((non-surgical or psychological or behavior* or behaviour* or cognitive or psychosocial or 
psycho-social or psychoeducation*) NEAR/3 (intervention* or treatment* or therap* or 
program* or modification)) 
 
(Coping NEAR/1 (skill* or behavior* or behaviour*)) 
 
((peer or psychosocial or social or patient) NEXT/1 support) 
 
(Psychotherapy or psychotherapies or CBT or counsel*ing or “self-management” or 
psychoeducation or (assistive NEAR/1 technolog*) or (assistive NEAR/1 device*) or education* 
or “health literacy” or “health information” or “self care” or exercis* or stretching or “resistance 
training” or “strength training” or running or jogging or swimming or walking or “physical 
endurance” or sports or sport or “physical activity” or treadmill* or bicycling or cycling or 
“physical conditioning” or “muscle strength*” or rehabilitation) 
 
 ((mobile NEAR/1 (health or rehabilitation)) or tele health or telehealth or telemedicine or e-
health or ehealth or m-health or mhealth or mobile based or (virtual NEAR/1 (medicine or 
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rehabilitation)) or ((remote or distance) NEAR/1 (medicine or rehabilitation or consultation)) or 
videoconferenc* or video conferenc* or tele conferenc* or teleconferenc* or tele education or 
tele-education or telementoring or tele-mentoring or tele-care or telecare or live video* or cell 
phone* or text messag*) 
 
((Oral or dental or periodontal or Gingival) NEAR/2 (rehabilitation or health or pathology or 
hygiene or care or therap* or treatment* or activit* or exercise* or disease*))  
 
((non pharmacological or nonpharmacological or multidisciplinary or multicomponent or 
interdisciplinary or multimodal) NEAR/1 (treatment or intervention or therap* or management))   
 
((Alternative or Complementary) NEAR/2 (medicine or therap* or treatment*)) 
 
(scleroderma* or “systemic sclerosis” or CREST syndrome*) 
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Supplementary File 2. Inclusion and exclusion coding manual 
 
Title/Abstract Coding Manual  
No: no original human data. If it is clear from the title or abstract that the article is not an 
original report, but rather a letter, editorial, systematic review, meta-analysis, case series, or case 
report, it is excluded. Conference or symposium abstracts are eligible.  
No: not about scleroderma/scleroderma patients. If the title or abstract do not describe the 
inclusion of participants with “scleroderma”, “systemic sclerosis” (SSc) or “CREST syndrome”, 
the study will be excluded. If the study reports data on people with SSc, along with people with 
other conditions, the study will be included if the SSc data are reported separately or if at least 
80% of the included participants have SSc.  
No: not a randomized controlled trial (RCT) with eligible comparators. If it clear from the 
title or abstract that the study is not an RCT that compares an intervention to an (1) inactive 
control condition (e.g., no treatment, waitlist control, usual care) or (2) another intervention, it 
will be excluded. If the trial includes fewer than 10 participants per trial arm, it is excluded.  
No: not about a non-pharmacological intervention. If it is clear from the title or abstract that 
the intervention is not non-pharmacological or non-surgical, then it is excluded. Eligible 
interventions include, but are not limited to, physical or occupational therapy, rehabilitation, 
exercise, psychological, self-management, educational, diet or nutrition, nursing, podiatry, and 
oral or dental hygiene. All pharmacological interventions, or interventions with a drug 
component, will be excluded. Interventions will be classified as having a drug component if any 
form of the active intervention ingredient was listed by the US Food and Drug Administration 
(FDA) in the Drugs@FDA database at the time of review. Use of probiotics will be included as a 
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dietary or nutrition intervention if delivered as a food product similar to products that could be 
obtained outside of a medical intervention (e.g., yoghurt). They will be excluded if they are 
products registered as a drug or delivered in pill format. Biologics will be excluded, even if 
autologous (i.e. skin grafting, stem cells), regardless of regulation status. 
No: does not target health outcomes or delivery of services.  If it is clear from the title or 
abstract that the intervention does not target physical or psychological health or the delivery of 
health and support services, it will be excluded.  
Yes: Study eligible for inclusion in full-text review.  
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Full Text Coding Manual  
No: no original human data. If the article is not an original report, but rather a letter, editorial, 
systematic review, meta-analysis, case series, or case report, it is excluded. Conference or 
symposium abstracts are eligible.  
No: not about scleroderma/scleroderma patients. If the study does not describe the inclusion 
of participants with “scleroderma”, “systemic sclerosis” (SSc) or “CREST syndrome”, the study 
will be excluded. If the study reports data on people with SSc, along with people with other 
conditions, the study will be included if the SSc data are reported separately or if at least 80% of 
the included participants have SSc.  
No: not a randomized controlled trial (RCT) with eligible comparators. If the study is not an 
RCT that compares an intervention to an (1) inactive control condition (e.g., no treatment, 
waitlist control, usual care) or (2) another intervention, it will be excluded. If the trial includes 
fewer than 10 participants per trial arm, it is excluded. 
No: not about a non-pharmacological intervention. If the intervention is not non-
pharmacological or non-surgical, then it is excluded. Eligible interventions include, but are not 
limited to, physical or occupational therapy, rehabilitation, exercise, psychological, self-
management, educational, diet or nutrition, nursing, podiatry, and oral or dental hygiene. All 
pharmacological interventions, or interventions with a drug component, will be excluded. 
Interventions will be classified as having a drug component if any form of the active intervention 
ingredient was listed by the US Food and Drug Administration (FDA) in the Drugs@FDA 
database at the time of review. Use of probiotics will be included as a dietary or nutrition 
intervention if delivered as a food product similar to products that could be obtained outside of a 
medical intervention (e.g., yoghurt). They will be excluded if they are products registered as a 
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drug or delivered in pill format. Biologics will be excluded, even if autologous (i.e. skin grafting, 
stem cells), regardless of regulation status. 
No: does not target health outcomes or delivery of services. If the intervention does not target 
physical or psychological health or the delivery of health and support services, it will be 
excluded.  
Yes: Study eligible for inclusion.  
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Supplementary File 3. Variables Included in Data Extraction Form 
 






Conflicts of interest 
Country 
Study eligibility criteria 
Recruitment setting and method 
Number of participants randomised 
Percent female 
Mean (standard deviation [SD]) age 
Type of SSc 
Mean (SD) years with SSc 
Notes 
 
Intervention and control group details  
 
Group name 
Number of participants randomised to group 
Number of participants analysed in group 
Description of intervention and comparator 
Qualifications of intervention providers  
Intervention setting 
Intervention length 
Number of sessions 
Length of sessions 
Tailoring  
Modifications  





Outcome type  
Outcome measure name 
Timepoints collected  
Measure of aggregation (e.g., mean, median) at post-test assessments 
Measure of dispersion (e.g., SD) at post-test assessments 
Number of participants analysed  
Other relevant results at post-test assessments 
Notes 
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